Spectral and Dialco Announce Dr. John Kellum to Be Featured as Keynote Lecturer at the 39th Vicenza Course on AKI and CRRT

Dr. Kellum Invited to Participate on Additional Featured Panels

TORONTO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), are pleased to announce that Dr. John Kellum, the Company’s CMO, will be featured as the keynote lecturer at the virtual 39th Vicenza Course on Acute Kidney Injury (AKI) and Continuous Renal Replacement Therapy (CRRT) from Tuesday, October 26, 2021, to Friday, October 29, 2021. Dr. Kellum will discuss the importance of industry-academia collaboration in sepsis research:

Keynote Lecture: Industry and Academia: joining the forces in AKI and Sepsis
October 30, 2021, at 7:30 AM Eastern Time

Additionally, Dr. Kellum has been invited to participate in in the following featured panels:

Cappuccino with Claudio Ronco: CRRT Technology Update
Host: Dr. Claudio Ronco; Guest: Dr. John Kellum and SAMI
October 27, 2021, at 11:00 AM Eastern Time – Sponsored by Dialco Medical Inc.

Symposium: Endotoxic Shock: From Pathophysiology to Advanced Targeted Solutions
Moderator: Dr. Claudio Ronco; Speakers: Dr. John Kellum and Dr. Silvia De Rosa
October 27, 2021, at 12:15 PM Eastern Time – Sponsored by Estor S.p.A

Meet the Expert: Biomarkers (EAA) – Guided Initiation of PMX Hemoperfusion in Sepsis
Moderator: Dr. Claudio Ronco; Speaker: Dr. John Kellum
October 28, 2021, at 10:10 AM Eastern Time – Sponsored by Spectral Medical Inc.

We invite you to join us at the Vicenza Course by clicking on the link below to watch the conference online via YouTube: https://www.youtube.com/user/VicenzaNephroCourses

Each session will be available for viewing via the YouTube link above during any time after the premiere of the Vincenza Course. After November 5, 2021, podcasts will be available on the Spectral website: https://spectraldx.com/investors

About Spectral

Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.

PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 300,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 330,000 patients are diagnosed with severe sepsis and septic shock in North America each year.

Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of proprietary platforms addressing renal replacement therapy (“RRT”) across the dialysis spectrum. SAMI is targeting the acute RRT market, while DIMI is targeting the chronic RRT market. Dialco is currently pursuing regulatory approval for U.S. in-home use of DIMI, which is based on the same RRT platform as SAMI, but will be intended for home hemodialysis use. DIMI recently received its FDA 510k clearance for use in hospital and clinical settings, and obtained its Health Canada license for use within Canadian hospitals, clinics and in home.

Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit www.spectraldx.com.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

Contact: